Insmed (INSM) Accounts Payables (2010 - 2026)
Insmed (INSM) posted quarterly Accounts Payables of $352.6 million for Q1 2026, up 51.52% year-over-year from $232.7 million in Q1 2025, and down 22.7% quarter-over-quarter from $456.1 million in Q4 2025.
Insmed (INSM) Accounts Payables (2010 - 2026) Analysis & Trends
Insmed's Accounts Payables history runs 17 years deep, the most recent figure standing at $352.6 million for Q1 2026.
- In Q1 2026, Accounts Payables rose 51.52% year-over-year to $352.6 million; the TTM figure through Mar 2026 stood at $352.6 million (up 51.52% YoY), while the FY2025 annual figure was $456.1 million, up 59.9% from the prior year.
- Accounts Payables for Q1 2026 stood at $352.6 million, down from $456.1 million in the prior quarter.
- The five-year high for Accounts Payables was $456.1 million in Q4 2025, with the low at $31.1 million in Q2 2022.
- The 5-year median for Accounts Payables is $258.9 million (2024), against an average of $251.8 million.
- Peak annual rise in Accounts Payables reached 116.62% in 2022, while the deepest fall reached 0.2% in 2022.
- Insmed's Accounts Payables stood at $182.1 million in 2022, then gained by 18.05% to $215.0 million in 2023, then surged by 32.66% to $285.2 million in 2024, then jumped by 59.9% to $456.1 million in 2025, then fell by 22.7% to $352.6 million in 2026.
- Business Quant data shows INSM's Accounts Payables at $352.6 million in Q1 2026, $456.1 million in Q4 2025, and $409.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 25.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 428.93 Mn |
| Mar 31, 2026 | 352.56 Mn |
| Dec 31, 2025 | 456.06 Mn |
| Sep 30, 2025 | 409.84 Mn |
| Jun 30, 2025 | 305.02 Mn |
| Mar 31, 2025 | 232.67 Mn |
| Dec 31, 2024 | 285.21 Mn |
| Dec 31, 2023 | 214.99 Mn |
| Dec 31, 2022 | 182.12 Mn |
| Jun 30, 2022 | 31.14 Mn |
| Mar 31, 2022 | 48.57 Mn |
| Dec 31, 2021 | 125.03 Mn |
| Sep 30, 2021 | 23.53 Mn |
| Jun 30, 2021 | 31.08 Mn |
| Mar 31, 2021 | 22.42 Mn |
| Dec 31, 2020 | 42.85 Mn |
| Sep 30, 2020 | 22.15 Mn |
| Jun 30, 2020 | 25.01 Mn |
| Mar 31, 2020 | 18.19 Mn |
| Dec 31, 2019 | 13.18 Mn |